

Public Summary

Summary for ARTG Entry: 42933 PROVERA Medroxyprogesterone acetate 5mg tablet blister pack (New Formula)

ARTG entry for Medicine Registered Pfizer Australia Pty Ltd Sponsor

Postal Address 38-42 Wharf Road, WEST RYDE, NSW, 2114

Australia

ARTG Start Date 7/01/1993 **Product category** Medicine

Approval area **Drug Safety Evaluation Branch**

Conditions

Conditions applicable to all therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.

Products

1. PROVERA Medroxyprogesterone acetate 5mg tablet

9/03/2017 **Product Type** Effective date Single Medicine Product

Permitted Indications

No Permitted Indications included on Record

Indication Requirements

No Indication Requirements included on Record

Standard Indications

No Standard Indications included on Record

Specific Indications

1. Carcinoma: Palliative treatment of recurrent and/or metastatic breast or renal cell cancer and of inoperable recurrent or metastatic endometrial carcinoma. 2. Endometriosis: For use in the treatment of visually proven (laparoscopy) endometriosis where the required end-point of treatment is pregnancy, or for the control of symptoms when surgery is contraindicated or has been unsuccessful. 3. Secondary Amenorrhoea proven not due to pregnancy: In amenorrhoea associated with a poorly developed proliferative endometrium, conventional oestrogen therapy may be employed in conjunction with medroxyprogesterone acetate. 4. Abnormal Uterine Bleeding: In the absence of organic pathology. 5. Adjunct to Oestrogen Therapy: Combination hormone replacement therapy should only be used in non-hysterectomised women.

See Product Information and Consumer Medicine Information for this product

Additional Product information

Container information

Туре	Material	Life Time	Temperature	Closure	Conditions
Blister Pack	PVC/AI	3 Years	Store below 30 degrees Celsius	Not recorded	Not recorded

Pack Size/Poison information

Pack Size

28 and 56 tablets Components

1. Medicine Component

Dosage Form

Route of Administration

Visual Identification **Active Ingredients**

Medroxyprogesterone acetate

Poison Schedule

(S4) Prescription Only Medicine

Tablet, uncoated

Pale blue, round tablets. One surface is engraved with the logo "286" on both sides of a break-score. The other surface is engraved with the logo "U"

5 mg

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at http://www.tga.gov.au/about/website-copyright.htm.